PERTH: Emyria Limited has signed an agreement with Zelira Therapeutics to collect data from patients treated with insomnia drug Zenivol through Emyria’s specialist clinical services.
Zelira is Perth-based company specialising in the development of cannabinoid-based medicines for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain.
Under the partnership, Emyria will collect longitudinal data on patients prescribed Zenivol for the treatment of insomnia and related conditions. Emyria will provide real-world data that will complement the existing clinical data-pack for Zenivol and be used to inform further clinical development and, ultimately, the path to product registration.
Zelira will pay Emyria up to $100,000 comprising an upfront fee of $50,000 along with a subscription fee for each patient enrolled in the study, up to a maximum of 100 participants. The initial term of the agreement is for 12 months, with Zelira having an option to extend the term to capture the required minimum of data for each patient.
Emyria Managing Director Dr Michael Winlo said: “We’re delighted to be working with Zelira Therapeutics, to realise the potential for a real-world evidence asset that will help to progress the commercialisation and regulatory acceptance of its medicinal cannabis products. Partnering with clinically-focused companies, such as Zelira, further supports our model of generating high-quality patient data to accelerate development of unregistered medicines for patients.”
Zelira Managing Director Dr Richard Hopkins said: “Australia’s commitment to developing a highly regulated market for prescription cannabis medicines, means this country is a global leader in collection of high-quality real-world data relating to patients treated with medicinal cannabis. We believe Emyria’s approach to collection and curation of patient data, underpinned by its clinical services, is best-in-class.
Being able to access real-world data, in real-time, from patients treated with Zenivol will have immediate benefit to our go-to-market strategy. This information will also inform the design of future clinical trials, reduce the risks and costs of development and accelerate the path to regulatory approval.”
Emyria Limited is a Real-World Evidence data company using its network of specialist clinical services and purpose-built, remote patient monitoring technologies and data platforms to accelerate the development and registration of new treatments and facilitate the implementation of valuable new care models.
Emyria’s model provides high quality care for patients with unmet needs while also generating high quality and ethically sourced clinical data. Emyria’s evidence is used by Emyria’a customers to pay for insights, conduct clinical trials and accelerate medical innovation.